2021 CMSC Annual Meeting

Tag: 7797Disease-modifying therapyDaniel Sellers, MSCS, PA-C* and Donald Negroski, MD, MS Center of Sarasota, Sarasota, FL

Late Breaking-Disease-modifying therapy

Early Experience with Cladribine Tablets in an Aging Patient Population

Background: Cladribine, a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, may disrupt the central immune cascade...

Read More